Sulfinpyrazone NEW
| Price | $58 |
| Package | 200mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-04-27 |
Product Details
| Product Name: Sulfinpyrazone | CAS No.: 57-96-5 |
| Purity: 98.1% | Supply Ability: 10g |
| Release date: 2025/04/27 |
Product Introduction
Bioactivity
| Name | Sulfinpyrazone |
| Description | Sulfinpyrazone (NSC-75925) is a uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. |
| In vivo | Sulfinpyrazone exerts significant electrophysiologic actions under various experimental conditions. It raises the ventricular fibrillation threshold as well as the mid diastolic threshold and prolongs the effective refractory period. In the acutely ischemic heart, it attenuates the effect of coronary occlusion on the ventricular fibrillation threshold but has no effect after reperfusion. A protective influence of the drug is also evident during sympathetic humoral stimulation with norepinephrine. The antifibrillatory effect of sulfinpyrazone is additive to the changes elicited by beta adrenergic blockade with practolol or cardiac membrane stabilization with lidocaine[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 64 mg/mL (158.23 mM), Sonication is recommended. DMSO : 40 mg/mL (98.89 mM), Sonication is recommended. |
| Keywords | uricosuric | Sulfinpyrazone | platelet | oral | NSC-75925 | NSC75925 | intermittent | Inhibitor | inhibit | gouty | G28315 | G 28315 | COX | arthritis | antithrombotic |
| Inhibitors Related | Bismuth Subsalicylate | Phenacetin | Ibuprofen | Acetaminophen | Salicylamide | Diclofenac sodium | Diclofenac Potassium | Paradol | Indomethacin sodium hydrate | Salicylic acid | Glafenine | Revaprazan hydrochloride |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Pain-Related Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Human Metabolite Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $58.00/200mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-04-27 | |
| $58.00/200mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-04-27 | |
| $10.00/25Kg/Drum |
VIP5Y
|
Hebei Mujin Biotechnology Co.,Ltd
|
2021-10-19 | |
| $1.10/1g |
VIP5Y
|
Dideu Industries Group Limited
|
2021-06-16 | |
| $1.00/1KG |
VIP7Y
|
Career Henan Chemical Co
|
2018-08-20 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY